Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females

Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 Vaccine, Cervarix® When Administered to Healthy Females According to the Prescribing Information in Korea

This Post Marketing Surveillance (PMS) will collect safety data on the use of GSK Biologicals' human papillomavirus (HPV) vaccine in the local target population of females as per the regulations of the Korean Food and Drugs Administration (KFDA).

Inclusion Criteria:

• Female subjects aged between and including, 10 to 25 years at the time of the first vaccination.
• Subjects who the investigator believes that they or their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for vaccination visits etc) should be enrolled in the PMS.
• Written informed consent obtained from the subject or the subjects' parent/ guardian.
• Subjects of childbearing potential must not be pregnant. Absence of pregnancy should be verified (e.g. urine pregnancy test) as per the investigator's clinical judgement.
• Subjects with no contraindication according to the local approved prescribing information.
• No previous administration of an HPV vaccine other than Cervarix®.
• No previous administration of more than two doses of Cervarix®.
• No planned administration of an HPV vaccine other than Cervarix® during the PMS